Dogwood Announces $5 Million Private Placement with CK Life Sciences Int’l., (Holdings) Inc.

The financing includes common shares only, with no warrants or other derivative securities.

Rhea-AI Summary

Dogwood Therapeutics (DWTX) entered into a securities subscription agreement for a $5 million investment from its largest shareholder, a CK Life Sciences subsidiary. Dogwood will issue 4,098,360 common shares at $1.22 per share, priced at-the-market under Nasdaq rules, with no warrants or other derivative securities. The private placement is expected to close on or prior to October 29, 2026.

Dogwood expects the proceeds to advance Halneuron Phase 3 preparatory activities and extend operational runway through March 2027, by which time it expects to finalize a pivotal Phase 3 program design. Its ongoing HAL-CINP Phase 2b trial evaluates Halneuron against placebo in 239 patients with chemotherapy-induced neuropathic pain, with topline data expected in November 2026. The primary endpoint measures the change in weekly average daily pain intensity from baseline to week four.

5 points · 0 major

MixediHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

0 major · 2 points

Hollow bars mark forward-looking points. How the balance works

Positive

• Moderate point. Forward-looking: it has not happened yet and may not happen.$5 million investment agreement adds planned funding from Dogwood’s largest shareholder, a CK Life Sciences subsidiary. 12% of market cap
• Minor point. Forward-looking: it has not happened yet and may not happen.Operational runway is expected to extend through March 2027 upon closing.
• Minor point. Forward-looking: it has not happened yet and may not happen.Phase 3 preparatory activities are expected to advance using the proceeds.
• Minor point. Forward-looking: it has not happened yet and may not happen.Pivotal Phase 3 program design is expected to be finalized by March 2027.
• Minor point. Forward-looking: it has not happened yet and may not happen.HAL-CINP Phase 2b topline data are expected in November 2026.

Negative

• Moderate point. Forward-looking: it has not happened yet and may not happen.4,098,360 new common shares at $1.22 per share will dilute existing holders.
• Minor pointPrivate placement closing remains pending, expected on or prior to October 29, 2026.

News Explained

The agreement is not yet closed; if it closes, issuing the agreed new common shares will increase Dogwood’s share count and reduce existing holders’ percentage ownership, so that dilution remains conditional on completion.

Argus 15 min delay 8 alerts

+14.98% vs previous close $1.40 last price 84.7x rel. volume Open Argus

Details

Market move: DWTX +14.98% vs previous close. $5 million private placement

$1.22 – $1.41 Day Range

$47.68M Mkt Cap at Last Price

On Oct 19, the day this news came out, the latest delayed price for DWTX is 14.98% above the previous close. Our momentum scanner has recorded 8 alerts for this stock so far that day. The latest delayed price is $1.40. Relative volume is exceptionally heavy at 84.7x the average.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Key Figures

Private placement proceeds: $5 million Common shares to be issued: 4,098,360 shares Price per share: $1.22 per share +3 more

Private placement proceeds

$5 million

Investment from CK Life Sciences subsidiary

Common shares to be issued

4,098,360 shares

Under the subscription agreement

Price per share

$1.22 per share

Private placement pricing

Expected operational runway

Through March 2027

Expected after the investment

Expected closing deadline

On or prior to October 29, 2026

Private placement

Topline data readout

November 2026

Halneuron Phase 2b CINP trial

Historical Context

1 past event · Latest: Sep 14

1 event

1. Sep 14

   Trial enrollment

   24h Move

   -4.9%

   Completed enrollment of 239 patients in the same Phase 2b trial ahead of November topline data.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

securities subscription agreement, private placement, regulation d, subcutaneous, +1 more

5 terms

securities subscription agreement financial

"entered into a securities subscription agreement for a $5 million investment"

A securities subscription agreement is a signed contract in which an investor agrees to buy a specified number of shares or other securities from an issuer and the issuer agrees to sell them. It spells out the price, payment timing and the promises and conditions both sides must meet before the deal is completed. For investors it is important because it creates a legal commitment that affects how much ownership, voting power and future value the investor will have — like signing a purchase agreement when reserving a house.

private placement financial

"The private placement is being priced at-the-market"

A private placement is a sale of securities directly to a selected group of investors, typically institutions or accredited investors, instead of through a public offering. It lets a company raise money faster and with fewer regulatory steps; for existing shareholders it matters because the newly issued shares, often sold at a discount, increase the share count and can dilute their ownership.

regulation d regulatory

"and/or Regulation D promulgated thereunder"

Regulation D is a set of rules that govern how companies can raise money from investors without going through the full process required for public stock offerings. It provides simplified options for private placements, making it easier for companies to seek investments from a smaller group of investors. For investors, it offers opportunities to invest in private companies, often with fewer restrictions, but also with different levels of risk and disclosure.

subcutaneous medical

"Participants received 8 subcutaneous doses of Halneuron® or placebo"

Subcutaneous means situated or applied just beneath the skin. In finance, the term can describe processes or investments that are hidden or not immediately visible, much like something placed under the skin that isn't easily seen from the outside. Recognizing subcutaneous activities helps investors understand underlying factors that may influence markets or asset values over time.

primary endpoint medical

"The primary endpoint for this study is the change from baseline"

The primary endpoint is the single main result a clinical study is designed to measure to decide if a treatment works, like the finish line in a race that tells you who won. Investors care because meeting or missing this goal drives regulatory decisions, future sales expectations and stock value — it turns trial data into a clear yes-or-no signal about a drug’s commercial prospects.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

- Largest Shareholder Increases Position as Dogwood Advances Halneuron^® Toward Topline Phase 2b Data Readout in November 2026 -

- Expected Proceeds from the Investment Enable Acceleration of Phase 3 Preparatory Activities -

ATLANTA, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (“Dogwood” or the “Company”), a company that focuses on developing first-in-class, new non-opioid medicines to treat pain and neuropathy, today announced that the Company has entered into a securities subscription agreement (the “Subscription Agreement”) for a $5 million investment from the Company’s largest shareholder, a subsidiary of CK Life Sciences Int’l., (Holdings) Inc. (“CKLS”). The investment comes as Dogwood continues to advance its ongoing Halneuron^® Phase 2b Chemotherapy Induced Neuropathic Pain (“CINP”) trial toward topline data readout in November 2026. Proceeds from this investment will enable the advancement of Phase 3 preparatory activities and extend operational runway through March 2027.

Pursuant to the terms of the Subscription Agreement, Dogwood will issue an aggregate of 4,098,360 shares of Common Stock at a price of $1.22 per share. The private placement is being priced at-the-market under the rules of The Nasdaq Stock Market. No warrants or other derivative securities are included in the transaction. The private placement is expected to close on or prior to October 29, 2026. The Company currently expects to use the net proceeds from the private placement to fund Phase 3 preparatory activities for Halneuron^® and for working capital and general corporate purposes.

“This investment by CK Life Sciences reflects their confidence in the potential of Halneuron^® and our HAL-CINP Phase 2b program,” said Greg Duncan, Chief Executive Officer of Dogwood Therapeutics. “Upon closing, these proceeds are expected to extend our runway through March 2027, by which time we expect to finalize a pivotal Phase 3 program design for Halneuron^® in CINP. We look forward to reporting topline data from the HAL-CINP trial in the coming weeks and value CK Life Sciences’ deepening commitment to Dogwood and Halneuron^®.”

Halneuron^® CINP Phase 2b Trial (“HAL-CINP”) Overview (NCT06848348)

HAL-CINP is a randomized, phase 2b clinical trial evaluating the efficacy and safety of Halneuron^® compared with placebo in 239 patients with moderate to severe neuropathic pain caused by prior platinum and/or taxane-based chemotherapy. Participants received 8 subcutaneous doses of Halneuron^® or placebo over a 14-day period and are followed for a total of 28 days for safety and efficacy. The primary endpoint for this study is the change from baseline to week four in the weekly average of daily 24-hour recall pain intensity scores. The study is being conducted at approximately 25 sites in the U.S. Secondary measures will assess Halneuron’s^® treatment effects on sleep, fatigue, neuropathy symptoms and overall patient health.

The shares of Common Stock described above are being offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and/or Regulation D promulgated thereunder, and have not been registered under the Securities Act or applicable state securities laws. Accordingly, the shares may not be offered or sold in the United States absent registration with the Securities and Exchange Commission (the “SEC”) or an applicable exemption from such registration requirements. 

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

About CKLS

CKLS is listed on The Stock Exchange of Hong Kong Limited (Stock Code: 0775). Bearing the mission of improving the quality of life, CKLS is engaged in the business of research and development, manufacturing, commercialization, marketing, sale of, and investment in products and assets which fall into three core categories – nutraceuticals, pharmaceuticals & diagnostics, and agriculture-related. CKLS is a member of the CK Hutchison Group.

About Dogwood Therapeutics

Dogwood Therapeutics (Nasdaq: DWTX) is a development-stage biopharmaceutical company focused on developing first-in-class, non-opioid medicines to treat pain and neuropathic disorders. The Dogwood research pipeline includes two first-in-class development candidates, Halneuron^® and SP16 IV.

Our lead product candidate, Halneuron^®, is in Phase 2b development to treat pain conditions including the neuropathic pain associated with chemotherapy treatment. Halneuron^® has been granted fast track designation from the FDA for the treatment of chemotherapy-induced neuropathic pain (“CINP”). Halneuron^® is a non-opioid, Na_V 1.7 analgesic which is a highly specific voltage-gated sodium channel modulator, a mechanism known to be effective for reducing pain transmission. In clinical studies, Halneuron^® treatment has demonstrated pain reduction in pain related to general cancer and in pain related to chronic CINP. SP16 IV is a low-density lipoprotein receptor-related protein-1 agonist (“LRP1”) with potential to treat neuropathy and prevent or repair nerve damage following chemotherapy. SP16’s activity as an LRP1 agonist in turn provides alpha-1-antitrypsin-like activity. Consistent with alpha-1-antitrypsin anti-inflammatory and immunomodulatory actions, SP16 preclinically demonstrated anti-inflammatory (analgesic) action via potential reductions in IL-6, IL-8, IL1B and TNF-alpha levels, as well as potential to repair damaged tissue via increases in pAKT and pERK that regulate fundamental processes like growth, proliferation and survival. The forthcoming SP16 IV Phase 1b CIPN trial is fully funded by the National Cancer Institute.

For more information, please visit www.dwtx.com.

Forward-Looking Statements:

Statements in this press release contain “forward-looking statements,” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “suggest,” “target,” “aim,” “should,” "will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Dogwood’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including risks related to the satisfaction of customary closing conditions related to the private placement and the Company’s ability to complete the private placement on the anticipated timeline or at all; the anticipated use of proceeds from the private placement; the completion, timing, enrollment, design and results of current and future clinical studies relating to Dogwood’s product candidates; whether interim or final clinical data will support continued development, regulatory submissions or approval; and Dogwood’s ability to finance its operations. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled “Risk Factors” in the most recently filed Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Dogwood undertakes no duty to update such information except as required under applicable law.

Investor Relations:

Dan Ferry
Managing Director
LifeSci Advisors, LLC
daniel@lifesciadvisors.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much is Dogwood raising in its private placement, and at what price?

Dogwood entered into an agreement for a $5 million investment through the issuance of 4,098,360 common shares at $1.22 per share. The investor is its largest shareholder, a CK Life Sciences subsidiary. No warrants or other derivative securities are included.

When does Dogwood expect HAL-CINP Phase 2b results?

Dogwood expects topline HAL-CINP Phase 2b data in November 2026. The trial compares Halneuron with placebo in 239 patients with moderate to severe neuropathic pain caused by prior platinum and/or taxane-based chemotherapy.

How is Dogwood’s HAL-CINP Phase 2b trial conducted?

HAL-CINP is a randomized trial in which participants received 8 subcutaneous doses of Halneuron or placebo over a 14-day period, with safety and efficacy follow-up totaling 28 days. It is conducted at approximately 25 U.S. sites. Secondary measures assess sleep, fatigue, neuropathy symptoms and overall patient health.